The case for & against
Bull & Bear analysis
Bullish
Exagen Inc. (NASDAQ:XGN) operates in the autoimmune diagnostics market, focusing on innovative testing solutions for conditions like rheumatoid arthritis and lupus, addressing significant unmet diagnostic needs. As a growing player in a market valued at over $2.2 billion, Exagen aims to capitalize on its differentiated biomarker offerings through strategic expansion and partnerships. The company is establishing a solid reputation amidst increasing competition, focusing on improved clinical outcomes and physician engagement.
Bull says
- ↑Q1 revenue $17.3M (+12% YoY), gross margin 59%, ASP $444 (+6%).
- ↑3% share in $2.2B market growing 5% annually supports expansion.
- ↑Testing volume +10% YoY to ~30K tests; new biomarkers boost reach.
- ↑Strong Buy consensus with $8.86 average PT implies ~100% upside.
- ↑Cash balance $22M; targeting positive free cash flow by 2027.
- ↑High growth and profitability factors; leverage remains manageable.
Bear says
- ↓Negative earnings yield and high volatility hamper financial stability.
- ↓Analyst revisions score weak and low institutional ownership signal skepticism.
- ↓Q1 adjusted EBITDA loss $2.2M, despite a 14% year-over-year improvement.
- ↓Average PT $3.87 implies ~14.7% downside from $4.54 current price.
- ↓Smaller size versus large diagnostics peers may limit scale efficiencies.
- ↓Risk of disruption from larger diagnostic firms entering autoimmune space.
Earnings Call · Q1 2026 · Mgmt. Guidance
Updated 05-14-2026neutral
Transcript signals
Bull points
- First quarter 2026 revenue reached 17.3 million, an increase of 12% compared to last year, reflecting continued deliberate execution across the business and record top line performance by growth in both testing volume and ASP.
- Testing volume grew 10% driven by continued momentum from the investments we made last year to upgrade and expand the commercial organization.
- a 4% improvement in sales productivity based on trailing 12 month volume per territory.
Bear points
- Our adjusted EBITDA loss was $2.2 million in the first quarter, despite a 14% improvement compared to last year, indicating continued challenges to achieving overall profitability.
- We had about two weeks in the end of January, early February, where we lost around 30% or so, a third of our volume for those two weeks, just related to that severe weather in the Northeast.
- we lost about a third of volume over the course of two solid weeks.
Read full transcript analysis ›